Introduction
The proteome is the complete collection of proteins in a cell, tissue, or organism. The human proteome is approximated to have more than 75,000 distinct proteins, of which over 20,000 have been identified and described thus far. The proteome undergoes continuous modifications in response to the specific requirements of a cell.
Clinical proteomics is the systematic study of proteins on a large scale. It is used to utilize this information in healthcare as thousands of proteins in biological samples such as blood or solid tissue are analyzed. Mass spectrometry, a popular technology, acts as a molecular weighing scale, detecting the presence of proteins in a sample by evaluating their mass. Subsequently, this diagnostic tool can compare the proteins detected in different samples.
What Are the Potential Benefits of Clinical Proteomics?
-
Identification of Biomarkers- The development of proteomics has made it possible to identify many potential illness indicators quickly. These could result in the development of evaluations that allow for more accurate and specific identification of illnesses for speedier treatment, improved diagnosis, or more successful treatment outcome tracking.
-
Molecular Imaging- Molecular imaging of tissue involves using real-time mass spectrometry (mass spectrometry is used to look at sequence molecules in the body and help scientists learn more about single cells) to identify diseased tissue based on its proteome profile compared to normal tissue. This technology can assist surgeons in accurately identifying cancerous tissue that has to be removed and aiding pathologists in accurately interpreting biopsy (tissue examination) samples.
-
Pharmaceutical Research and Development- The proteome of a disease can provide precise and up-to-date information on the performance of a particular molecule and serve as a useful tool for identifying unique targets for developing new drugs.
What Is the Impact on the Patients?
-
Proteomics can enhance the understanding of diseases and track the effectiveness of treatments in real time, enabling more personalized diagnostics and treatment approaches.
-
Proteomics is primarily in the research phase due to the substantial costs and specialized expertise required for mass spectrometry in human proteome analysis, the difficulties in identifying biomarkers (biological indicators), and the dynamic character of a constantly evolving system.
-
Trials are focused on various biomarkers that have been identified through proteomics. Notably, it is being studied for its potential to detect chronic kidney disease at an early stage and being utilized to provide analysis of cancerous tissue during surgical procedures.
What Are the Challenges of Clinical Proteomics?
Although proteomics has proven highly beneficial for promoting discovery-based research, several challenges currently hinder its widespread application.
-
Alteration in Blood Proteins- Sample collection in any clinical laboratory necessitates careful planning. Blood protein profiles may undergo alterations due to the duration between sample collection and analysis.
-
Biological Variation- Changes in protein expression amongst people based on age, gender, or race are part of variation in any biochemical study. Variations may also arise in a patient based on age, time of day, or hunger level. Therefore, clinicians must carefully plan the studies and be aware of the limitations of proteomic technology to discover the changes that affect proteins and how they alter them.
-
Protein Profile- The protein composition of a certain sample can vary based on the collection, handling, and storage methods employed, as well as the analytical technique utilized. In biomarker research, samples are often collected from multiple locations and subsequently divided into sets for discovery (training) and sets for testing in a random manner.
-
Non-specific Binding- The most significant biochemical material in the laboratory is plasma, also known as serum. Plasma is the most difficult proteomics sample to work with since it contains the human proteome, which is large and diverse, consisting of a wide range of protein levels. However, many potentially useful indicators may be lost during this process due to non-specific binding or the removal of peptides and proteins naturally associated with many carrier proteins.
-
Expense of Proteomics- Proteomics is only employed in a limited capacity in hospital laboratories due to the high expense of the technology. Most proteomics technologies require complex apparatus or equipment, significant computer power, and pricey supplies to function properly.
What Is the Future Prognosis?
The science of proteomics is progressing swiftly, aided by the efforts of various organizations such as the Human Proteome Organization (HUPO).
-
Combining proteomics and genomes in the future could lead to a deeper understanding of diseases and better treatment options.
-
Proteomics is currently best used as a clinical study tool for finding biomarkers and looking into what causes diseases because it is complicated.
-
To make whole proteome analysis a useful clinical tool, one needs to create cheap and easy technology to gain access to and show that it can be used to identify diseases.
Conclusion
The widespread application of proteomics impacts medical research as it could result in better prognostic and diagnostic testing, the identification of new pharmacological targets, and more individualized therapy for each patient. Proteomics has shown promise in biomarker detection; however, further research is needed to improve the efficacy and reliability of these techniques before they are commonly used in clinical laboratories. Traditional proteomics technologies need to be more suitable for application in normal clinical labs due to the need for specialized personnel and expensive equipment. As a result, classical proteomics research will likely remain very valuable in identifying a specific group of genetic markers associated with a given disease; following these findings, conventional biochemical and immunological investigations can be carried out. However, new multiplexing technologies like protein chips and grids will shortly allow for even faster analytical procedures for clinical proteomics.
